{"id":236608,"date":"2026-09-09T11:28:16","date_gmt":"2026-09-09T05:58:16","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=236608"},"modified":"2026-09-09T11:28:16","modified_gmt":"2026-09-09T05:58:16","slug":"balaxi-pharmaceuticals-share-price-buy-hold-or-sell","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell\/","title":{"rendered":"Balaxi Pharmaceuticals: Should You Buy, Hold, or Sell Right Now?"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Balaxi Pharmaceuticals share price Rs 24.27 (NSE), up nearly 4% today, well off its 52-week high. 52-week range Rs 15.20 to Rs 47.75. Recent quarterly profit has been steadily improving.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Balaxi Pharmaceuticals Ltd share price is trading around Rs 24.3, up nearly 4 percent today, roughly 49 percent below its 52-week high of Rs 47.75 but above its 52-week low of Rs 15.20. Q1 FY27 revenue grew 15.5 percent year on year to Rs 79.69 crore, with net profit up sharply to Rs 1.30 crore from Rs 0.29 crore, continuing a steady quarter-on-quarter improvement across the past year. Full-year FY25 revenue grew 21.9 percent, with the company turning a profit of Rs 25.07 crore, a genuine turnaround from a net loss of Rs 2.39 crore in FY24. The stock trades at a rich 53.05 times earnings against the pharmaceutical sector average near 38 times.<\/p>\n<\/p><\/div>\n<p>Balaxi Pharmaceuticals share price is up nearly 4 percent today, trading around Rs 24.3 on the NSE, roughly 49 percent below its 52-week high of Rs 47.75, above its 52-week low of Rs 15.20. With a steadily improving trend continuing in Q1 FY27 following a genuine FY25 turnaround, investors are asking whether this pharmaceutical exports company is a stock to buy at the current level, a hold, or a sell.<\/p>\n<p>This Balaxi Pharmaceuticals stock analysis walks through the Q1 FY27 numbers, the FY25 turnaround, valuation against the pharmaceutical sector, shareholding pattern and the technical setup, using figures sourced from public filings.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=balaxipharma_bhs\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell\/#About_Balaxi_Pharmaceuticals\" title=\"About Balaxi Pharmaceuticals\">About Balaxi Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell\/#Balaxi_Pharmaceuticals_Share_Price_Today_Key_Levels\" title=\"Balaxi Pharmaceuticals Share Price Today: Key Levels\">Balaxi Pharmaceuticals Share Price Today: Key Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell\/#Balaxi_Pharmaceuticals_Financial_Performance\" title=\"Balaxi Pharmaceuticals Financial Performance\">Balaxi Pharmaceuticals Financial Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell\/#Valuation_Check_Is_Balaxi_Pharmaceuticals_Share_Price_Expensive\" title=\"Valuation Check: Is Balaxi Pharmaceuticals Share Price Expensive?\">Valuation Check: Is Balaxi Pharmaceuticals Share Price Expensive?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell\/#Technical_Signals_What_the_Chart_Shows\" title=\"Technical Signals: What the Chart Shows\">Technical Signals: What the Chart Shows<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell\/#Shareholding_Pattern\" title=\"Shareholding Pattern\">Shareholding Pattern<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell\/#Why_Investors_Are_Watching_Balaxi_Pharmaceuticals\" title=\"Why Investors Are Watching Balaxi Pharmaceuticals\">Why Investors Are Watching Balaxi Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell\/#Risks_and_Factors_to_Watch\" title=\"Risks and Factors to Watch\">Risks and Factors to Watch<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell\/#Balaxi_Pharmaceuticals_Share_Price_Target_What_the_Data_Suggests\" title=\"Balaxi Pharmaceuticals Share Price Target: What the Data Suggests\">Balaxi Pharmaceuticals Share Price Target: What the Data Suggests<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell\/#Balaxi_Pharmaceuticals_Should_You_Buy_Hold_or_Sell_Right_Now\" title=\"Balaxi Pharmaceuticals: Should You Buy, Hold, or Sell Right Now?\">Balaxi Pharmaceuticals: Should You Buy, Hold, or Sell Right Now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell\/#Q1_Is_Balaxi_Pharmaceuticals_a_good_stock_to_buy_right_now\" title=\"Q1. Is Balaxi Pharmaceuticals a good stock to buy right now?\">Q1. Is Balaxi Pharmaceuticals a good stock to buy right now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell\/#Q2_What_is_the_Balaxi_Pharmaceuticals_share_price_today\" title=\"Q2. What is the Balaxi Pharmaceuticals share price today?\">Q2. What is the Balaxi Pharmaceuticals share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell\/#Q3_What_is_the_Balaxi_Pharmaceuticals_share_price_target\" title=\"Q3. What is the Balaxi Pharmaceuticals share price target?\">Q3. What is the Balaxi Pharmaceuticals share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell\/#Q4_Is_Balaxi_Pharmaceuticals_profitable\" title=\"Q4. Is Balaxi Pharmaceuticals profitable?\">Q4. Is Balaxi Pharmaceuticals profitable?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell\/#Q5_What_does_Balaxi_Pharmaceuticals_do\" title=\"Q5. What does Balaxi Pharmaceuticals do?\">Q5. What does Balaxi Pharmaceuticals do?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell\/#Q6_What_is_Balaxi_Pharmaceuticals_market_capitalisation\" title=\"Q6. What is Balaxi Pharmaceuticals&#8217; market capitalisation?\">Q6. What is Balaxi Pharmaceuticals&#8217; market capitalisation?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"About_Balaxi_Pharmaceuticals\"><\/span><strong>About Balaxi Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Before deciding on Balaxi Pharmaceuticals share price, it helps to understand the underlying business. Balaxi Pharmaceuticals Ltd. is engaged in pharmaceutical exports and distribution, serving international markets with branded and generic medicines.<\/p>\n<p>As a pharmaceutical exports company, Balaxi Pharmaceuticals completed a genuine turnaround to profitability in FY25, and the company&#8217;s quarterly results have continued to show a steady, improving trend since, without a single reversal.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Balaxi_Pharmaceuticals_Share_Price_Today_Key_Levels\"><\/span><strong>Balaxi Pharmaceuticals Share Price Today: Key Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below summarises where Balaxi Pharmaceuticals share price stands right now against its recent trading range and market value.<\/p>\n<table border=\"1\" cellpadding=\"6\" cellspacing=\"0\" style=\"border-collapse:collapse;width:100%;\">\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>Balaxi Pharmaceuticals CMP (NSE)<\/td>\n<td>Rs 24.27<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 47.75<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 15.20<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>Approximately Rs 129 crore<\/td>\n<\/tr>\n<\/table>\n<p>Balaxi Pharmaceuticals share price is up today, though it remains well below its 52-week high, reflecting the market&#8217;s continued caution around this small-cap turnaround story.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Stock Data<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Balaxi_Pharmaceuticals_Financial_Performance\"><\/span><strong>Balaxi Pharmaceuticals Financial Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Balaxi Pharmaceuticals share price trend is closely tied to how these numbers evolve each quarter. Balaxi Pharmaceuticals reported Q1 FY27 (June 2026 quarter) revenue of Rs 79.69 crore, up 15.5 percent year on year from Rs 68.96 crore, with net profit growing sharply to Rs 1.30 crore from Rs 0.29 crore, continuing a steady quarter-on-quarter improvement: Rs 0.29 crore, Rs 0.21 crore, Rs 0.31 crore, Rs 0.61 crore, and now Rs 1.30 crore.<\/p>\n<p>For the full year FY25, the company reported revenue of Rs 294.92 crore, up 21.9 percent year on year, with net profit of Rs 25.07 crore, a genuine turnaround from a net loss of Rs 2.39 crore in FY24, confirming the improved profitability has been sustained across both the annual and most recent quarterly results.<\/p>\n<table border=\"1\" cellpadding=\"6\" cellspacing=\"0\" style=\"border-collapse:collapse;width:100%;\">\n<tr>\n<th>Period<\/th>\n<th>Revenue<\/th>\n<th>Net Profit<\/th>\n<th>Comment<\/th>\n<\/tr>\n<tr>\n<td>Q1 FY27 (Jun 2026)<\/td>\n<td>Rs 79.69 crore<\/td>\n<td>Rs 1.30 crore<\/td>\n<td>+15.5% revenue; profit up sharply YoY<\/td>\n<\/tr>\n<tr>\n<td>FY25 (full year)<\/td>\n<td>Rs 294.92 crore<\/td>\n<td>Rs 25.07 crore<\/td>\n<td>+21.9% revenue; turned around from a Rs 2.39 crore loss in FY24<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_Check_Is_Balaxi_Pharmaceuticals_Share_Price_Expensive\"><\/span><strong>Valuation Check: Is Balaxi Pharmaceuticals Share Price Expensive?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Any view on Balaxi Pharmaceuticals share price should start from these valuation multiples. Balaxi Pharmaceuticals share price currently reflects a price to earnings ratio of about 53.05 times trailing earnings, a premium to the broader pharmaceutical sector average of roughly 38 times, a figure reflecting the small trailing earnings base following the recent turnaround. The price to book ratio stands near 0.5 times, with return on equity at just 0.57 percent.<\/p>\n<p>Debt to equity of 0.23 is low. Given the very small trailing earnings base, investors should focus on the steady, improving quarterly trend rather than the currently rich PE, which should moderate as the recovery continues to build.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Technical_Signals_What_the_Chart_Shows\"><\/span><strong>Technical Signals: What the Chart Shows<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Price action here often foreshadows the next move in Balaxi Pharmaceuticals share price. Balaxi Pharmaceuticals share price is up nearly 4 percent today, positioned roughly 49 percent below its 52-week high of Rs 47.75 and above its 52-week low of Rs 15.20. A stock trading here, backed by a steady, improving quarterly trend since the FY25 turnaround, typically signals the market cautiously rewarding a small-cap recovery story.<\/p>\n<p>Trading volumes remain moderate, so investors should track Balaxi Pharmaceuticals share price alongside continued confirmation of the improving trend in coming quarters, rather than reacting to any single day&#8217;s move at these technical levels.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Balaxi Pharmaceuticals&#8217; live price and technical levels.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Shareholding_Pattern\"><\/span><strong>Shareholding Pattern<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Shifts here can influence Balaxi Pharmaceuticals share price more than headline news on some sessions. Balaxi Pharmaceuticals is a promoter-led pharmaceutical exports and distribution company that completed a genuine turnaround in FY25. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company&#8217;s latest exchange filing.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Investors_Are_Watching_Balaxi_Pharmaceuticals\"><\/span><strong>Why Investors Are Watching Balaxi Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Genuine and sustained turnaround since FY25:<\/strong> The company moved from a net loss in FY24 to a solid profit in FY25, with the improving trend continuing steadily through five consecutive quarters since.<\/li>\n<li><strong>Steady quarterly improvement without reversal:<\/strong> Profit has grown every quarter over the past year, from Rs 0.29 crore to Rs 1.30 crore, a consistent pattern worth noting.<\/li>\n<li><strong>Low financial leverage:<\/strong> A debt to equity ratio of just 0.23 gives the company reasonable financial flexibility.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Risks_and_Factors_to_Watch\"><\/span><strong>Risks and Factors to Watch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Very small trailing earnings base:<\/strong> With a trailing return on equity of just 0.57 percent, the company&#8217;s earnings base remains small, and the current PE should be read with caution.<\/li>\n<li><strong>Significant pullback from 52-week high:<\/strong> The stock has fallen roughly 49 percent from its high, and investors should understand the reasons behind this decline before assuming the current level represents value.<\/li>\n<li><strong>Pharmaceutical exports competitive market:<\/strong> Balaxi Pharmaceuticals competes against numerous other pharmaceutical exports and distribution companies.<\/li>\n<li><strong>Small-cap liquidity risk:<\/strong> As a small-cap stock with a market capitalisation of approximately Rs 129 crore, trading liquidity can be more limited than larger pharmaceutical peers.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Balaxi_Pharmaceuticals_Share_Price_Target_What_the_Data_Suggests\"><\/span><strong>Balaxi Pharmaceuticals Share Price Target: What the Data Suggests<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Until then, Balaxi Pharmaceuticals share price remains best tracked through live, verified data rather than a single fixed number. Balaxi Pharmaceuticals does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. What the data shows is a company with a steady, improving trend since its FY25 turnaround.<\/p>\n<p>Investors who want live, updated research can check the Univest Screener, and should consult a SEBI-registered investment adviser given the small scale involved.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Balaxi_Pharmaceuticals_Should_You_Buy_Hold_or_Sell_Right_Now\"><\/span><strong>Balaxi Pharmaceuticals: Should You Buy, Hold, or Sell Right Now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This is the core question behind Balaxi Pharmaceuticals share price right now. The Balaxi Pharmaceuticals buy or sell decision depends on whether the steady improvement can continue to build.<\/p>\n<p><strong>The case for buying:<\/strong> Investors who believe the FY25 turnaround reflects a durable recovery, and who are comfortable with small-cap risk, may find the current level worth considering.<\/p>\n<p><strong>The case for holding:<\/strong> Existing shareholders who already track Balaxi Pharmaceuticals&#8217; steady improvement may prefer to stay invested and monitor continued execution.<\/p>\n<p><strong>The case for waiting:<\/strong> Investors wanting the trailing earnings base to build further before committing fresh capital may prefer to wait for that confirmation.<\/p>\n<p>Weigh this against your own risk tolerance and consult a SEBI-registered investment adviser if unsure.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Balaxi Pharmaceuticals share price reflects a pharmaceutical exports company showing a steady, improving quarterly trend since its genuine FY25 turnaround, trading well below its 52-week high. This article is for informational purposes and not a personalised investment recommendation.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h3><span class=\"ez-toc-section\" id=\"Q1_Is_Balaxi_Pharmaceuticals_a_good_stock_to_buy_right_now\"><\/span><strong>Q1. Is Balaxi Pharmaceuticals a good stock to buy right now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Balaxi Pharmaceuticals has shown a steady, improving quarterly trend since its FY25 turnaround from a loss, with Q1 FY27 profit reaching Rs 1.30 crore. This suits investors comfortable with small-cap risk who believe the recovery is durable.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q2_What_is_the_Balaxi_Pharmaceuticals_share_price_today\"><\/span><strong>Q2. What is the Balaxi Pharmaceuticals share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Balaxi Pharmaceuticals share price is trading around Rs 24.3 on the NSE, up nearly 4 percent today. The stock&#8217;s 52-week high is Rs 47.75 and its 52-week low is Rs 15.20.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q3_What_is_the_Balaxi_Pharmaceuticals_share_price_target\"><\/span><strong>Q3. What is the Balaxi Pharmaceuticals share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Balaxi Pharmaceuticals does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Investors can check live research on the Univest Screener and consult a SEBI-registered adviser.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q4_Is_Balaxi_Pharmaceuticals_profitable\"><\/span><strong>Q4. Is Balaxi Pharmaceuticals profitable?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Yes, Balaxi Pharmaceuticals turned around to a full-year FY25 profit of Rs 25.07 crore from a net loss of Rs 2.39 crore in FY24, with the improving trend continuing through Q1 FY27.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q5_What_does_Balaxi_Pharmaceuticals_do\"><\/span><strong>Q5. What does Balaxi Pharmaceuticals do?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Balaxi Pharmaceuticals is engaged in pharmaceutical exports and distribution, serving international markets with branded and generic medicines.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q6_What_is_Balaxi_Pharmaceuticals_market_capitalisation\"><\/span><strong>Q6. What is Balaxi Pharmaceuticals&#8217; market capitalisation?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Balaxi Pharmaceuticals has a market capitalisation of approximately Rs 129 crore.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Has B.L. Kashyap and Sons outperformed the Nifty 50 in the last year?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. B.L. Kashyap and Sons returned -18.42% over the past year while the Nifty 50 returned -4.61% over the same period, based on NSE closing prices to 9 September 2026.\"}},{\"@type\":\"Question\",\"name\":\"How does B.L. Kashyap and Sons vs Nifty 50 look over 5 years?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Over five years B.L. Kashyap and Sons has returned +133.76% compared with the Nifty 50's +35.35%, so in the B.L. Kashyap and Sons vs Nifty 50 comparison the stock has been ahead over this longer horizon.\"}},{\"@type\":\"Question\",\"name\":\"What is the B.L. Kashyap and Sons share price today compared to Nifty 50?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"B.L. Kashyap and Sons share price stood at Rs 56.57 on NSE, while the Nifty 50 traded at 23,490.45 based on the same closing data window.\"}},{\"@type\":\"Question\",\"name\":\"What is the 52-week high and low of B.L. Kashyap and Sons?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"B.L. Kashyap and Sons's 52-week high is Rs 73.00 and its 52-week low is Rs 40.32, based on NSE data.\"}},{\"@type\":\"Question\",\"name\":\"Why does B.L. Kashyap and Sons show bigger price swings than the Nifty 50?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"B.L. Kashyap and Sons carries concentrated exposure to its own sector and business cycle, while the Nifty 50 spreads risk across 50 large companies, so company-specific news moves B.L. Kashyap and Sons's price more sharply than the diversified index, a key reason the B.L. Kashyap and Sons vs Nifty 50 return gap varies across time frames.\"}},{\"@type\":\"Question\",\"name\":\"Is B.L. Kashyap and Sons a good long-term investment compared to a Nifty 50 index fund?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"B.L. Kashyap and Sons's suitability depends on an investor's risk appetite, since single-stock exposure carries higher concentration risk than a diversified Nifty 50 index fund; long-term investors should weigh the B.L. Kashyap and Sons vs Nifty 50 return history alongside the company's fundamentals and consult a SEBI-registered advisor.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Balaxi Pharmaceuticals share price up today, with a recent turnaround explained after a loss-making FY24.<\/p>\n","protected":false},"author":29,"featured_media":236605,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-236608","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["236605"],"rank_math_title":["Balaxi Pharmaceuticals Share Price: Buy or Sell"],"rank_math_description":["Balaxi Pharmaceuticals share price up today, with a recent turnaround explained after a loss-making FY24, a balanced view."],"rank_math_focus_keyword":["Balaxi Pharmaceuticals share price | Density Target: 1.2-1.5%"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/balaxi-pharmaceuticals-share-price-buy-hold-or-sell.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/236608","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=236608"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/236608\/revisions"}],"predecessor-version":[{"id":236610,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/236608\/revisions\/236610"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/236605"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=236608"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=236608"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=236608"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}